Milvexian, the experimental blood thinner co-developed by Bristol Myers Squibb and Johnson & Johnson, may launch soon, but there are legitimate reasons to be cautious about its commercial prospects in the pharmaceutical landscape. The pharma landscape is highly competitive, with numerous alternatives already on the market that have established efficacy and safety profiles, posing a significant challenge to Milvexian’s acceptance. Insurers will ask a LOT of questions before granting coverage.
The regulatory environment remains stringent, and delays in the approval process could affect the entry of new pharmaceutical drugs into the market. Additionally, the uptake of new medications often hinges on healthcare providers’ willingness to adopt them and on patients’ perceptions of their safety and effectiveness. Ongoing clinical trials and published research will play a crucial role in shaping the opinions of both these key stakeholders, thus influencing the product’s overall success. As such, while the potential for Milvexian is undeniable, caution is warranted until its commercial trajectory becomes clearer.
Here are the biggest challenges.
1ne. The first Phase III trial failed
OK, the trial is past news, but the fallout remains with a skeptical market. The most significant setback occurred when the Phase III LIBREXIA-ACS trial was stopped early after an independent monitoring committee concluded milvexian was unlikely to outperform standard therapy in patients recovering from acute coronary syndrome (heart attacks and unstable angina). There were no major new safety concerns, but the drug simply wasn’t expected to provide enough additional clinical benefit. (BioPharma Dive)
For any cardiovascular drug, a failed Phase III study substantially reduces expected peak sales even if it was conducted a while ago. Physicians will have many questions and may be skeptical.
2wo. The Factor XI hypothesis is under pressure
Milvexian belongs to a new class of anticoagulants called Factor XIa inhibitors. The promise has been compelling:
- maintain stroke prevention
- significantly reduce bleeding
- replace or complement current direct oral anticoagulants
However, several companies developing Factor XI inhibitors have experienced disappointing late-stage results in different indications, raising questions about whether inhibiting Factor XI consistently delivers meaningful clinical benefit. (BioPharma Dive)
3hree. It competes against one of the best drugs in medicine
Ironically, Bristol Myers already markets one of the world’s leading anticoagulants:
- Eliquis
Eliquis has:
- enormous physician familiarity
- excellent efficacy
- a strong safety profile
- years of real-world evidence
For physicians to switch, milvexian would need to demonstrate either:
- superior efficacy,
- dramatically lower bleeding,
- or meaningful convenience.
Being merely “similar” is unlikely to justify widespread adoption.
4our. The commercial window is narrowing
By the time Milvexian reaches market (if approved), several dynamics may reduce its opportunity:
- generic competition for existing anticoagulants
- Competing Factor XI programs
- payer pressure to use lower-cost options
That makes blockbuster projections harder to achieve.
5ive. Investors have become more skeptical
Before the Phase III failure, analysts viewed milvexian as a potential multibillion-dollar product. After the ACS trial stopped early:
- Bristol Myers shares declined.
- Analysts reduced expectations.
- Some questioned whether the disappointing ACS result might foreshadow challenges in other indications, although atrial fibrillation and stroke prevention remain biologically distinct. (fiercebiotech.com)
But It May Still Succeed If….
It is important not to overstate the negative case. Two pivotal studies remain ongoing:
- Prevention of stroke in patients with Atrial fibrillation
- secondary stroke prevention
These represent larger commercial opportunities than acute coronary syndrome, and they involve different patient populations and dosing strategies. Bristol Myers and Johnson & Johnson have continued investing in these trials because they believe the biology may be more favorable. (STAT)
The investment thesis for milvexian has clearly weakened because:
- One major Phase III indication has already failed,
- The Factor XI drug class has produced mixed clinical results,
- Eliquis sets an exceptionally high efficacy and safety standard,
- and commercial competition will be intense.
Its ultimate success now depends largely on whether the ongoing atrial fibrillation and stroke prevention trials demonstrate a clinically meaningful advantage—particularly reduced bleeding without sacrificing protection against thrombotic events. Those remaining trials are likely to determine whether milvexian becomes a niche therapy or a significant new anticoagulant.
